Cilofexor

Cilofexor is a medication primarily used in the treatment of liver diseases, particularly nonalcoholic steatohepatitis (NASH). It is an agonist of the farnesoid X receptor (FXR), a nuclear receptor that plays a crucial role in the regulation of bile acid, lipid, and glucose metabolism.

Mechanism of Action

Cilofexor works by activating the farnesoid X receptor (FXR), which is highly expressed in the liver and intestine. Activation of FXR leads to a decrease in bile acid synthesis and an increase in bile acid transport and excretion. This helps to reduce liver inflammation and fibrosis, which are key features of nonalcoholic steatohepatitis (NASH).

Clinical Uses

Cilofexor is being investigated for its potential benefits in treating nonalcoholic steatohepatitis (NASH), a severe form of nonalcoholic fatty liver disease (NAFLD). NASH is characterized by liver inflammation and damage caused by a buildup of fat in the liver. If left untreated, it can progress to cirrhosis and liver cancer.

Side Effects

Common side effects of cilofexor include gastrointestinal symptoms such as nausea, diarrhea, and abdominal pain. Some patients may also experience elevated levels of liver enzymes, which should be monitored during treatment.

Research and Development

Cilofexor is currently undergoing clinical trials to evaluate its efficacy and safety in patients with nonalcoholic steatohepatitis (NASH). Preliminary results have shown promise, with significant improvements in liver histology and reductions in liver fat content.

See Also

• Nonalcoholic steatohepatitis
• Farnesoid X receptor
• Nonalcoholic fatty liver disease
• Liver disease